MARKER THERAPEUTICS (MRKR)
(Delayed Data from NSDQ)
$2.80 USD
+0.15 (5.52%)
Updated Oct 4, 2024 02:30 PM ET
After-Market: $2.88 +0.08 (2.86%) 7:28 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MRKR 2.80 +0.15(5.52%)
Will MRKR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MRKR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRKR
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
MRKR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MRKR
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Marker Therapeutics GAAP EPS of -$0.25 beats by $0.24, revenue of $1.17M
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
MRKR Stock Earnings: Marker Therapeutics Beats EPS for Q2 2024
Marker Therapeutics Excels in Lymphoma Treatment Study